FTN Midwest Downgrades Barrier Therapeutics (BTRX) to Neutral
BTRX Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 1
FTN Midwest downgrades Barrier Therapeutics (Nasdaq: BTRX) from Buy to Neutral.
Barrier Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the field of dermatology in the United States.
Barrier Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the field of dermatology in the United States.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Barclays Cuts Price Target and Estimates on NetApp (NTAP); Disappointing Qtr, But There Is Hope
- JPMorgan Downgrades RailAmerica Inc. (RA) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
FTN MidwestSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
